Epidemiology of ST131 in Besançon University Hospital

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02853708

Acronym

coliST131

Enrollment

300

Registered

2016-08-03

Start date

2015-06-30

Completion date

2017-01-31

Last updated

2017-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Escherichia Coli Infections

Keywords

E. coli, extended-spectrum beta-lactamase, molecular epidemiology, risk factors

Brief summary

The sequence type 131 (ST131) is a predominant lineage among extraintestinal pathogenic Escherichia coli. It plays a major role in the worldwide dissemination of E. coli that produce extended-spectrum beta-lactamase (ESBL). The aim of this study was to describe the epidemiology of ESBL producing ST131clonal group in our university hospital. All patients with an infection due to ESBL E. coli will be prospectively included for a 2-year period. ST131 isolates will be identified and risk factors associated to ST131 will be determined in comparison to non-ST131 ESBL E. coli.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients infected with ESBL producing E. coli

Exclusion criteria

* Patients known to be carrier or infected in the previous year, patients only colonised with ESBL producing E. coli.

Design outcomes

Primary

Measure	Time frame	Description
Risk factors associated to ESBL ST 131 infections	up to 2 years	Time of hospitalization

Countries

France

Outcome results